Inhibikase Therapeutics, Inc.
IKT
$2.37
$0.010.42%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -2.27% | 3.40% | -7.32% | -5.40% | -1.67% |
| Total Depreciation and Amortization | -84.98% | -84.55% | 1,429.91% | 2,547.76% | 10,241.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.35% | -18.33% | 0.79% | 1.26% | -35.96% |
| Change in Net Operating Assets | 586.66% | 227.62% | 231.12% | 37.09% | 53.06% |
| Cash from Operations | 5.24% | 15.97% | 17.58% | -4.23% | -1.72% |
| Capital Expenditure | 100.00% | 100.00% | 94.16% | 94.16% | 94.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -101.91% | 174.47% | 165.73% | 174.04% | 190.47% |
| Cash from Investing | -101.91% | 173.64% | 164.93% | 172.83% | 189.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -55.78% | -57.90% | -95.36% | 19,354.88% | 19,353.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -57.21% | -59.34% | -97.75% | 4,204.00% | 4,271.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -253.62% | 103.90% | 95.09% | 105.89% | 123.24% |
